Results 241 to 250 of about 208,148 (266)

Human medicines European public assessment report (EPAR): Imatinib Accord, imatinib, Precursor Cell Lymphoblastic Leukemia-Lymphoma,Dermatofibrosarcoma,Myelodysplastic-Myeloproliferative Diseases,Leukemia, Myelogenous, Chronic, BCR-ABL Positive,Hypereosinophilic Syndrome, Date of authorisation: 30/0

Case Medical Research, 2019

semanticscholar   +1 more source

[Regression of the Philadelphia chromosome (bcr/abl)-positive myelo- and megakaryopoiesis after Imatinib (STI571) therapy in chronic myelogenous leukemia (CML)].

Der Pathologe, 2005
In chronic myeloid leukemia following therapy with Imatinib (STI571) hematologic and cytogenetic response is associated with conspicuous changes of bone marrow morphology. However, it is not known to which extent these alterations are accompanied by a loss of the bcr/abl translocation. To study regression of the leukemic cell population we recruited 14
J, Thiele, H M, Kvasnicka, E, Varus, S, Kriener, K, Engels, P, Staib, E S, Ollig, M, Griesshammer, C F, Waller, H, Pfeifer, A, Schmitt-Gräff   +10 more
openaire   +1 more source

Human medicines European public assessment report (EPAR): Imatinib Teva, imatinib, Leukemia, Myelogenous, Chronic, BCR-ABL Positive,Precursor Cell Lymphoblastic Leukemia-Lymphoma,Myelodysplastic-Myeloproliferative Diseases,Hypereosinophilic Syndrome,Dermatofibrosarcoma, Date of authorisation: 07/01/

Case Medical Research, 2018

semanticscholar   +1 more source

[Marked reduction of BCR-ABL fusion chromosome positive cells with interferon therapy combined with short-term imatinib in chronic myelogenous leukemia].

Gan to kagaku ryoho. Cancer & chemotherapy, 2003
A 71-year-old man with chronic myelogenous leukemia received interferon therapy for 21 months, but did not have complete cytogenetic response. Imatinib was then added to the former therapy. Imatinib was prescribed for only 12 days and discontinued because of severe erythema.
Atsushi, Ajima, Naoya, Takayama, Yuichi, Hasegawa, Hiroshi, Kojima, Toshiro, Nagasawa   +4 more
openaire   +1 more source

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells

Nature Network Boston, 1996
B. Druker, S. Tamura, E. Buchdunger, S. Ohno, G. Segal, S. Fanning, J. Zimmermann, N. Lydon   +7 more
semanticscholar   +1 more source

Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer

Ca-A Cancer Journal for Clinicians, 2023
Laura A Huppert, Hope S Rugo
exaly  

Antibiotic resistance in the patient with cancer: Escalating challenges and paths forward

Ca-A Cancer Journal for Clinicians, 2021
Amila K Nanayakkara, Vance G Fowler, Kevin Outterson   +2 more
exaly  

Evolving standards of care and new challenges in the management of HER2‐positive breast cancer

Ca-A Cancer Journal for Clinicians, 2020
Ciara C O’sullivan, Grace D Cullen, Grace M Choong   +2 more
exaly  

Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society

Ca-A Cancer Journal for Clinicians, 2020
Carmen E Guerra, Kevin C Oeffinger, Louise C Walter   +2 more
exaly  

Tumor board presentation of a woman with metastatic, hormone receptor‐positive, mismatch repair‐deficient endometrial cancer

Ca-A Cancer Journal for Clinicians, 2022
Gini F Fleming, Jennifer A Bennett
exaly